Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Aspects Concerning the Use of the SARS-CoV‑2 Receptor Binding Domain as a Target for Preventive Vaccines

19 Apr 2021

Abstract excerpt

The development of recombinant COVID-19 vaccines has resulted from scientific progress made at an unprecedented speed during 2020. The recombinant spike glycoprotein monomer, its trimer, and its recombinant receptor-binding domain (RBD) induce a potent anti-RBD neutralizing antibody response in animals. In COVID-19 convalescent sera, there is a good correlation between the antibody response and potent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Immunotherapy and Immune Responses
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34075345
DOI: 10.1021/acscentsci.1c00216

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Aspects Concerning the Use of the SARS-CoV‑2 Receptor Binding Domain as a Target for Preventive VaccinesPMID 34075345Read ↗

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.Semantic proximity Read ↗

Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodiesSemantic proximity Read ↗

Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding DomainSemantic proximity Read ↗

Elucidation of cellular targets and exploitation of the receptor‐binding domain of SARS‐CoV‐2 for vaccine and monoclonal antibody synthesisSemantic proximity Read ↗

SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity.Semantic proximity Read ↗

Spike Proteins of SARS –CoV-2: a detailed perspective on structure, receptor binding, antigenicity, vaccine development and neutralizationSemantic proximity Read ↗

Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse ModelSemantic proximity Read ↗

Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motifSemantic proximity Read ↗

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopesSemantic proximity Read ↗

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.Semantic proximity Read ↗

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike proteinSemantic proximity Read ↗

A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.